An estimated 60 million people worldwide have the chronic skin condition, psoriasis, according to the latest results of the Global Psoriasis Atlas (GPA).

The availability of testing for COVID-19 has been widened to include groups beyond NHS frontline staff.

The Commission of Human Medicines (CHM)Expert Working Group on coronavirus (COVID-19) has concluded that there is currently insufficient evidence to establish a link between use of ibuprofen, or other non-steroidal anti-inflammatory drugs (NSAIDs), and susceptibility to contracting COVID-19 or the worsening of its symptoms.

New guidelines issued by NICE to maximise the safety of children and adults who have dermatological conditions treated with drugs affecting the immune response during the COVID-19 pandemic. 

PsoProtect is an international registry for health care providers to report outcomes of COVID-19 in individuals with psoriasis.

We are working remotely to abide and support the current Government instructions, but we will continue to provide the services you require, although under these uncertain times, restrictions may mean it takes us a little longer to deal with your needs and enquiries.

If you have either psoriasis and/or psoriatic arthritis and are worried about the Coronavirus (COVID-19) and how it may affect you, go to the NHS website or the UK official government website.

Why not support PAPAA when you shop online. PAPAA is registered with Amazon Smile, so if you use the dedicated page PAPAA gets a donation from Amazon. 

Taking multiple medicines? Support the Yellow Card scheme by reporting suspected side effects

The Medicines and Healthcare products Regulatory Agency (MHRA) launches a week long social media campaign to raise awareness about the importance of reporting suspected side effects using the Yellow Card Scheme.

We have a limited number of FREE spaces available for our Psoriasis in Practice (PIP) course. The course is for Health Care Professionals (HCPs) and runs until 29th April 2020.